| Original language | English (US) |
|---|---|
| Pages (from-to) | 437-439 |
| Number of pages | 3 |
| Journal | JAMA Oncology |
| Volume | 6 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2020 |
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: JAMA Oncology, Vol. 6, No. 3, 03.2020, p. 437-439.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials
AU - Atkinson, Thomas M.
AU - Dueck, Amylou C.
AU - Satele, Daniel V.
AU - Thanarajasingam, Gita
AU - Lafky, Jacqueline M.
AU - Sloan, Jeff A.
AU - Basch, Ethan
N1 - Funding Information: Funding/Support: Research reported in this publication was supported by the Cancer Moonshot (US National Cancer Institute U01 CA233046), as well as the Funding Information: National Cancer Institute of the National Institutes of Health under award numbers U10CA180821, U10CA180882, and UG1CA189823 (to the Alliance for Clinical Trials in Oncology NCORP Research Base; Jan C. Buckner, MD, contact PI), U10CA180790, U10CA180838, and P30CA008748, which partially supports the Patient-Reported Outcomes, Community-Engagement, and Language Core Facility used to complete this investigation. Funding Information: Institute during the conduct of the study. Dr Thanarajasingam reported grants from National Institutes of Health during the conduct of the study. Dr Lafky reported grants from National Institutes of Health during the conduct of the study. Dr Basch reported grants from National Cancer Institute, grants from Patient-Reported Outcomes Research Institute, personal fees from Memorial Sloan Kettering Cancer Center, personal fees from Dana-Farber Cancer Institute, personal fees from Research Triangle Institute/CMS, personal fees from CareVive Systems, personal fees from Sivan Healthcare, and personal fees from Self Care Catalysts outside the submitted work. No other disclosures were reported.
PY - 2020/3
Y1 - 2020/3
UR - http://www.scopus.com/inward/record.url?scp=85077196579&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077196579&partnerID=8YFLogxK
U2 - 10.1001/jamaoncol.2019.5566
DO - 10.1001/jamaoncol.2019.5566
M3 - Letter
C2 - 31876902
AN - SCOPUS:85077196579
SN - 2374-2437
VL - 6
SP - 437
EP - 439
JO - JAMA Oncology
JF - JAMA Oncology
IS - 3
ER -